Browse News

Found 128 articles

• Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital

  9/21/2023

  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr. Robert T. Foster to the Board.

• New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program

  9/21/2023

  Hepion Pharmaceuticals, Inc. announced results from a study with in which the anti-cancer activity of Hepion’s lead drug candidate, rencofilstat, was tested in a high through-put screen on 850 cancer cell lines spanning 28 types of cancer at the PRISM lab at the Broad Institute of MIT and Harvard.

• Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference

  9/21/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that its Chief Executive Officer, Robert Foster, PharmD, PhD, will participate in a panel discussion during the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 9:45 a.m. ET in NYC.

• Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer

  9/19/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced new research findings uncovering a previously unknown mechanism by which Hepion’s lead drug candidate, rencofilstat, may exert anti-cancer activity.

• Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis

  9/14/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced positive results from a translational research study in which Hepion’s lead drug candidate, rencofilstat, was administered to diseased human lung tissue from patients with idiopathic pulmonary fibrosis (“IPF”).

• Hepion Pharmaceuticals Announces Management Changes - September 06, 2023

  9/6/2023

  Hepion Pharmaceuticals, Inc. announced that Stephen Harrison, M.D., has been appointed as Consultant Medical Director.

• 

  Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space

  7/31/2023

  Intercept’s failure to secure FDA approval for obeticholic acid (OCA) tablets in non-alcoholic steatohepatitis shines a light on safety challenges in the space, experts told BioSpace.

• Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023

  6/15/2023

  Hepion Pharmaceuticals, Inc. announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2023 taking place June 21 - 24, 2023 in Vienna, Austria and digitally.

• Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat

  6/15/2023

  Hepion Pharmaceuticals, Inc. announced that the Data and Safety Monitoring Board has met to review the current data for the ASCEND-NASH Phase 2b trial and has issued a “study may proceed without modification” clearance.

• Theralase(R) Announces Appointment of New Independent Director

  6/6/2023

  Theralase Technologies Inc. is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc.

• 

  Akero’s NASH Candidate Clears Phase IIb, Cuts Liver Fat by up to 65%

  6/5/2023

  Non-alcoholic steatohepatitis patients treated with the company’s efruxifermin saw significant improvements in liver fat and biomarkers of liver damage, fibrosis and cardiometabolic health.

• Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences

  5/24/2023

  Hepion Pharmaceuticals, Inc. announces that its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, and its Quantitative Systems Pharmacologist, Caroline Zhao, PharmD, will present at the 2023 Canadian Society for Pharmaceutical Sciences Annual Symposium being held in Toronto, Canada from May 24 to May 26, 2023.

• 

  Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat

  5/22/2023

  The 61-patient study met the primary endpoint of improved physiologic liver function and secondary endpoints, which included established non-alcoholic steatohepatitis biomarkers, Hepion reported Monday.

• Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

  5/22/2023

  Hepion Pharmaceuticals, Inc. today announced positive topline results from its recently completed Phase 2 ALTITUDE-NASH clinical trial.

• Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat

  5/19/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that it expects to release topline results from the Phase 2 ALTITUDE-NASH clinical trial before the market opens on Monday, May 22, 2023.

• Hepion Pharmaceuticals, Inc. Announces Reverse Stock Split - May 10, 2023

  5/10/2023

  Hepion Pharmaceuticals, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 4:01 p.m. Eastern Time , May 10, 2023.

• Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023

  4/17/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that an abstract highlighting its lead drug candidate, rencofilstat, will be presented by its Chief Scientific Officer, Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting, which is being held April 15-19, 2023, in Orlando, Florida.

• Hepion Pharmaceuticals Expands SAB with Appointments of Four Liver Disease KOLs

  3/30/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces the addition of four new internationally recognized thought leaders to its Scientific Advisory Board (“SAB”), effective immediately.

• Hepion Pharmaceuticals to Participate in ACS-JPS Webinar on AI Drug Development

  3/16/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announces that its Chief Executive Officer, Robert Foster, PharmD, PhD, and its Senior Vice President for Clinical Pharmacology and Analytics, Patrick Mayo, PhD, will be presenting during a webinar entitled “How Artificial Intelligence is Changing Drug Discovery” on Thursday, March 23rd at 1:00 p.m. Eastern Time.

• EPO Decision to Grant European Patent for Rencofilstat Further Strengthens Hepion’s Patent Portfolio

  3/2/2023

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that the European Patent Office (“EPO”) has granted European Patent No. EP 3886813, covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat.